Omni Healthcare's Analgesic Drug Cetaprin Has a 40 Percent Share

Omni Healthcare's analgesic drug Cetaprin has a 40 percent share in the analgesics market in the country of Terrania. Its closest competitor, Febex, has a 25 percent share in the market, while four other analgesic brands split the remainder. Which statement indicates that Cetaprin is a cash cow according to the BCG matrix?

A) The Terrania market for healthcare products is expanding rapidly.
B) Omni Healthcare often takes money from other strategic business units to support Cetaprin.
C) Febex is rapidly gaining market share over Cetaprin due to aggressive marketing efforts.
D) The demand for analgesic drugs in the Terrania market is expected to maintain a low-growth, high-share status
E) A customer survey shows that Cetaprin users do not prefer it to other analgesics in the market.